Malaria
At TAD, we lead effective in vivo evaluation of malaria interventions
At TAD we provide specialized in vivo evaluation services for antimalarial drug and vaccine candidates, supporting pharmaceutical and research teams at every stage of development: from hit-to-lead (H2L) to post-commercialization.
Our humanized mouse model (TADhuMouse® Model) infected with Plasmodium falciparum is a unique and powerful tool to generate translational data with high predictive value for human response.
What you get
Our goal is to map the function of efficacy of the drug or vaccine against the Plasmodium parasite. Each study is designed to answer key questions around.
Efficacy
How does your drug work in vivo?
We define the therapeutic mechanism of a drug, that is, how the treatment affects to the different parasite stages and the population dynamics while interfering in the biological cycle of Plasmodium spp. in vivo.
· Key outcomes: speed of action, stage specificity, compatibility for combination therapies, optimal treatment design, sterile-protection (vaccine efficacy)
Potency
How much drug you need to cure in humans?
We measure the specific potency of the treatment, that is, how much amount of drug is necessary to kill a erythrocyte infected with Plasmodium spp.
· Key outcomes: optimal regimes of use, total human dose prediction.
Antimalarial
resistance
What is the risk of resistance development?
We assess the potential for resistance emergence in vivo through deep genomic and phenotypic analyses.
· Key outcomes: whole genome sequency, measure of degree of resistance, deep analysis of mutations, impact on total human dose.
Antimalarial
drug-induced
hemolysis
Is your compound safe for G6PD-deficient populations?
Using our human G6PD-deficient blood in vivo model, we quantify hemolytic effects of antimalarials and help define safety margins.
· Key outcomes: drug-induced hemolysis, basal erythrocyte instability, dose-dependent hemolytic effect.
Solutions by
Development Stage
Our platform is designed to adapt. Depending on the phase of drug discovery you are at, we offer specific tools and study packages to reduce uncertainty and support data-driven decisions.
Explore our solutions by development stage:
Hit to lead
2
Lead optimization
3
Candidate selection
4
Clinical study
Your partner in advancing malaria research
We offer fully tailored experimental designs, targeting
different parasite stages and/or strains,
under robust industrial standards